This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention top 5 articles from VIVA 17
Click Here to Manage Email Alerts
From Sept. 11 to Sept. 15, 2017, VIVA Physicians held its annual conference in Las Vegas.
Cardiology Today’s Intervention provided onsite coverage and interviewed a number of experts on the event’s most important presentations and compiled a list of the top presentations from the conference, including percutaneous vs. surgical cutdown for access-site closure, the benefits of a drug-coated balloon in hemodialysis arteriovenous fistulae lesions, the results of the ILLUMENATE trial, benefits of a peripheral drug-eluting stent, the 2-year outcomes of the IN.PACT Global trial, and much more.
Percutaneous system for access-site closure beneficial vs. surgical cutdown
LAS VEGAS — Percutaneous closure of large-bore arterial access sites was associated with positive outcomes compared with surgical cutdown.
The percutaneous closure device (Perclose ProGlide, Abbott Vascular) was associated with fewer blood transfusions and infections, lower mortality and shorter length of stay compared with surgical cutdown, Darren Schneider, MD, associate professor and chief of vascular and endovascular surgery at the NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, said.
DCB beneficial in hemodialysis arteriovenous fistulae lesions
LAS VEGAS — In patients with dysfunctional hemodialysis arteriovenous fistulae, adding a DCB to treatment with percutaneous transluminal angioplasty was safe and improved patency, a researcher reported.
Researchers randomly assigned 285 patients at 23 centers with dysfunctional hemodialysis arteriovenous fistulae, all of whom received PTA, to further treatment with the DCB (Lutonix 035, Bard Peripheral Vascular) or a control balloon of similar design but without a drug.
ILLUMENATE: DCB yields durable treatment effect at 2 years
LAS VEGAS — New data from the ILLUMENATE EU randomized controlled trial demonstrate higher primary patency and a lower rate of clinically driven target lesion revascularization at 2 years after treatment with a DCB, compared with percutaneous transluminal angioplasty.
Researchers for the trial randomly assigned 294 patients with symptomatic femoropopliteal disease on a 3:1 basis to receive the DCB (Stellarex, Spectranetics/Philips) or PTA. The DCB was approved by the FDA in July.
Peripheral DES shows long-term benefit in real-world cohort
LAS VEGAS — A drug-eluting peripheral stent showed long-term benefits through 4 years in real-world patients with a variety of comorbidities.
The postmarket surveillance study consisted of the first 905 patients implanted with the DES (Zilver PTX, Cook Medical) in Japan, with no exclusion criteria. Michael D. Dake, MD, the Thelma and Henry Doelger professor of cardiovascular surgery and medical director of the catheterization and angiography laboratories at Stanford Health Care, presented subgroup analyses that evaluated performance of the DES in patients with chronic renal failure, no patent runoff vessels and in-stent restenosis.
IN.PACT Global: Real-world 2-year outcomes encouraging for peripheral DCB
LAS VEGAS — Use of a DCB conferred positive outcomes in more than four of five patients with symptomatic femoropopliteal disease at 2 years.
The DCB (IN.PACT Admiral, Medtronic) was evaluated in 1,406 real-world patients (mean age, 69 years; 68% men) with symptomatic femoropopliteal disease, defined as Rutherford class 2 to 4, some of whom had de novo in-stent restenosis, lesions longer than 15 cm and/or chronic total occlusion.